Viridian Therapeutics Files Q1 2025 10-Q
Ticker: VRDN · Form: 10-Q · Filed: May 6, 2025 · CIK: 1590750
| Field | Detail |
|---|---|
| Company | Viridian Therapeutics, Inc.\De (VRDN) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
**VRDN Q1 10-Q filed. Financials and biz ops details out.**
AI Summary
Viridian Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial data points and disclosures relevant to investors are included in this report.
Why It Matters
This 10-Q filing provides investors with a quarterly update on Viridian Therapeutics' financial health and operational performance, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a biotechnology company, Viridian Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250506 (date) — Filing date
- MIRAGEN THERAPEUTICS, INC. (company) — Former company name
- SIGNAL GENETICS, INC. (company) — Former company name
FAQ
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period ending March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 6, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What was Viridian Therapeutics previously known as?
Viridian Therapeutics was formerly known as MIRAGEN THERAPEUTICS, INC. and SIGNAL GENETICS, INC.
What is the company's business address?
The business address is 221 Crescent Street, Suite 103A, Waltham, MA 02453.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).